Skip to main content

Table 6 Cardiovascular risk factors, markers of diabetes severity, therapeutics and duration of follow-up for patients with (CVEV = 1) and without (CVEV = 0) cardiovascular events

From: Can cardiac computed tomography predict cardiovascular events in asymptomatic type-2 diabetics?: results of a long term follow-up

Univariate analysis CVEV = 1 CVEV = 0 p
Hypertension, CT (%) 100 92 ns
Hypercholesterolemia, CT (%) 80 70.3 ns
Increased waist circunference, CT (%) 87.5 84.1 ns
Metabolic syndrome, CT (%) 70 69.3 ns
Duration of diabetes, CT (years, mean ± sd) 16 ± 8 13 ± 9 ns
Diabetic neuropathy, CT (%) 44.4 21.4 ns
Diabetic retinopathy/nephropathy, CT (%) 33.3 38.6 ns
Hemoglobin A1c, CT (%, mean ± sd) 7.6 ± 1.3 8.3 ± 1.8 ns
Microalbuminuria, CT (mg/24h, mean ± sd) 171.9 ± 291.4 45.1 ± 122.6 ns
Serum C-reactive protein, CT (mg/dL, mean ± sd) 0.4 ± 0.2 0.4 ± 0.4 ns
Percutaneous revascularization, CT (%) 20 5.3 ns
Antiplatelets, CT (%) 70 46.7 ns
Statins, CT (%) 80 66.7 ns
ACE inhibitor/ARB, CT (%) 100 84 ns
Oral hypoglycaemic therapy, CT (%) 80 88 ns
Insulin therapy, CT (%) 60 49.3 ns
Hemoglobin A1c, Fup (%, mean ± sd) 7.7 ± 1.5 7.6 ± 1.6 ns
Microalbuminuria, Fup (mg/24h, mean ± sd) 39.3 ± 46.8 39.9 ± 118.4 ns
Serum C-reactive protein, Fup (mg/24h, mean ± sd) 0.7 ± 0.4 0.5 ± 0.4 ns
Antiplatelets, Fup (%) 66.7 45.8 ns
Statins, Fup (%) 55.6 56.2 ns
ACE inhibitor/ARB, Fup (%) 77.8 79.2 ns
Oral hypoglycaemic therapy, Fup (%) 83.9 86.3 ns
Insulin therapy, Fup (%) 66.7 53.4 ns
Duration of follow-up (months, mean ± sd) 45.7 ± 15.6 45.2 ± 13.0 ns
  1. Legend: CT – evaluated when computed tomography was performed; for therapeutics, it includes changes performed following CT; Fup – evaluated at time of follow-up; p- significance level; ACE - angiotensin-converting-enzyme; ARB - angiotensin receptor blocker.